Fourth in the World, First in Africa: How Zimbabwe’s Medicines Regulator Reached the Summit | The Second Great Zimbabwe Economic Journal · Entry 40 | TeteGetty.com
TeteGetty.com
The Second Great Zimbabwe Economic Journal · Entry 40
2 July 2026
The Second Great Zimbabwe Economic Journal · Entry 40 · Health, Industry & the Continent
MCAZ Reaches WHO Maturity Level 4 · The Highest Standard in Medicines Regulation on Earth

Fourth in the World, First in Africa: How Zimbabwe’s Medicines Regulator Reached the Summit

Quietly, and against every expectation the world holds of it, Zimbabwe has just done something no other African nation has ever done. The Medicines Control Authority of Zimbabwe (MCAZ) has attained the World Health Organisation’s Global Benchmarking Maturity Level 4 — the highest tier of medicines regulation there is. Only three other countries on the planet have ever reached it. This entry explains what that means, why a sanctioned and underestimated nation just out-performed most of the developed world, and — crucially — what it could unlock for our economy, our health, and the whole continent.

What Level 4 Means A Club of Four Made & Trusted at Home The Export Prize Africa’s Medicine Sovereignty
4th
Country in the World at Level 4
1st
In All of Africa
ML4
The Highest WHO Standard
~2 yrs
From Level 3 to the Summit
The world has a habit of picturing Zimbabwe as a place of shortages and crises. So let it sit with this: in the exacting science of regulating medicines, our small, sanctioned country now stands in a group of four — ahead of Britain, ahead of Germany, ahead of nearly everyone. Excellence, it turns out, was never a matter of wealth. It was a matter of will.
Entry 40 · on the day Zimbabwe reached the top of the world in one quiet, vital thing.
The News

What Just Happened — and Why It Is Enormous

Let us state it plainly, because it deserves to be said without hedging. The Medicines Control Authority of Zimbabwe (MCAZ) — the body that decides which medicines, vaccines and medical devices are safe enough to reach a Zimbabwean’s bloodstream — has been assessed by the World Health Organisation and awarded Maturity Level 4 (ML4), the highest rating in the WHO’s global system for judging a country’s medicines regulator. With it, Zimbabwe becomes the fourth country in the world, and the very first in Africa, to reach that summit.

To feel the weight of that, you need only see the company it keeps. Before Zimbabwe, only three nations on earth had ever been rated ML4: Singapore, South Korea and Saudi Arabia. Not the United Kingdom. Not Germany. Not most of the wealthy world whose regulators we are so often told to admire. A country under sanctions, written off in a hundred headlines, has just built an institution that the WHO ranks among the four best-run on the planet. This is not luck, and it is not an accident. It is what focused African competence looks like when nobody is watching.

The Standard

What “Maturity Level 4” Actually Means

The WHO measures every country’s medicines regulator using a Global Benchmarking Tool with four rungs. It is, in effect, a global ladder of trust.

LEVEL 1
Some basic elements exist
LEVEL 2
Partly functioning
LEVEL 3
Stable & well-functioning
LEVEL 4 ★
Advanced & continuously improving

Zimbabwe climbed from Level 3 (June 2024) to Level 4 in roughly two years — the top of the ladder.

Plain Language · Tichakurukura Pachikuru
Think of it like a restaurant hygiene rating, but for the entire system that keeps a nation’s medicines safe. Level 1 means a few rules exist on paper. Level 3 — which Zimbabwe reached in 2024 — means a solid, reliable system is fully working. Level 4, the top, means the regulator is not only excellent but is constantly improving itself, is transparent to the public, makes decisions based on risk and evidence, and runs on modern digital systems. It is the difference between “we do the job well” and “we are among the best in the world at it, and getting better.” Zimbabwe is now the latter.

The Company

A Club of Four

Here is the picture that ought to be on every front page in the country. Membership of the ML4 club, in the order each nation joined it:

The World’s Level 4 Regulators · Year Attained
Zimbabwe joins an elite group of four
Singapore and South Korea (2022), Saudi Arabia (2023) — and now Zimbabwe (2026), the fourth in the world and the first on the African continent. Most large, wealthy regulators are not formally benchmarked at this level at all.

Notice what that list is, and what it is not. It is three of the most advanced, best-resourced economies on earth — and Zimbabwe. It is not a story of money buying excellence; if it were, the list would look entirely different. It is a story of a poor country choosing, deliberately, to be world-class at one thing that truly matters — and then doing the unglamorous, years-long work to get there. For a continent so often told that quality is something it must import, Zimbabwe has just planted a flag: the best can be built here, by us, at home.

Why It Pays

What a Top Regulator Actually Unlocks

This is an economic journal, so let us be concrete about why a regulatory rating is not a dry technicality but a genuine economic prize. A world-class regulator is a key that opens doors that were previously locked to us.

🏭
Make medicines at home
International buyers and partners trust products approved by a top-tier regulator — so it becomes viable to manufacture medicines in Zimbabwe rather than import nearly everything.
🚚
Export across the continent
“Made in Zimbabwe, approved by an ML4 regulator” is a passport. Our factories can sell medicines regionally and continentally with credibility others cannot match.
💰
Unlock donor & global funds
Access to major internationally-funded procurement programmes for vaccines and medicines often depends on regulatory maturity. The door widens.
🧰
Attract pharmaceutical investment
Investors build factories where the rules are clear, modern and respected. Regulatory excellence is a magnet for the capital that creates skilled jobs.
The Beneficiation Thread — Now in Medicine
Readers of this journal will recognise the pattern instantly. We have argued it about lithium, about crops, about power, about our data: do not ship out the raw thing and buy back the finished one at a premium — make the finished thing here, and keep the value at home. Medicine is the same story in a white coat. A country that can regulate to the world’s highest standard can manufacture to it — turning Zimbabwe from a mere importer of others’ pills into a maker and exporter of its own. That is health sovereignty and economic sovereignty in a single dose.

The Continent

Africa’s Medicine Sovereignty — and Zimbabwe’s Gift to It

This achievement belongs to Zimbabwe, but its meaning is continental, which is why it also speaks to the pages of the Africa Journal. The COVID years taught Africa a brutal lesson it must never forget: a continent that imports the overwhelming majority of its medicines and vaccines is a continent that can be left last in the queue when the world panics. Medicine sovereignty — the ability to make, test and trust our own health products — is not a luxury. It is a matter of survival.

Zimbabwe’s leap directly strengthens that continental project. Its regulatory maturity feeds into the operationalisation of the African Medicines Agency (AMA), the body meant to harmonise and lift standards across the continent. Through reliance agreements and memoranda of understanding — MCAZ has signed them with regulators including Zambia’s ZAMRA, Botswana’s BoMRA and South Africa’s SAHPRA — one strong regulator lets its neighbours lean on its work, cutting duplication and speeding safe medicines to patients across borders. Zimbabwe has not just climbed the ladder; it can now hold it steady for others to climb behind it.

How It Was Actually Done
No miracle — method. Building on its 2024 Level 3 status, MCAZ did the demanding work Level 4 requires: digitalising its dossier submissions and inspections, strengthening pharmacovigilance (the ongoing tracking of medicine safety), and — notably — embracing radical transparency by publishing its assessment and inspection reports for the public to see. As MCAZ’s own Caroline Samatanga framed the mission, it was a journey of “continuous improvement and transparency” requiring legal, technical and institutional reform. Ordinary excellence, repeated daily, until it became extraordinary.
Tete Getty’s Take

This Is What We Are Actually Capable Of

I want every Zimbabwean, at home and in the diaspora, to pause and take this in, because we are so rarely given permission to be proud. While the world recites its familiar catalogue of our troubles, a team of our own scientists, pharmacists, inspectors and administrators quietly built an institution that the World Health Organisation now rates among the four finest on the planet — level with Singapore, ahead of nearly everyone. They did it under sanctions. They did it with a fraction of the budgets their peers enjoy. They did it while being told, endlessly, that this kind of excellence was not for people like us. And they did it anyway.

That is the lesson I want to carry out of this entry, far beyond medicine. Our chronic problem was never a shortage of ability — it was a shortage of belief, and a habit of importing our confidence along with our goods. MCAZ has just shown the whole nation, and the whole continent, a different way: pick a thing that matters, refuse to accept that world-class is someone else’s birthright, and do the patient, unshowy work until you are simply the best. If we can do it with medicines regulation, we can do it with the medicines themselves — and with our minerals, our food, our technology, our institutions. This is the Africa-first future made real: not begging for quality, but building it, and then selling it back to a world that doubted us.

So let us celebrate MCAZ properly, and then let us copy them relentlessly. Let the factories rise to match the regulator. Let a child in Buhera one day swallow a tablet that was invented, made, tested and trusted entirely at home — and let the same tablet be trusted in Lusaka, in Lagos, in Nairobi, because it carries a Zimbabwean seal the world respects. We reached the summit of the world in one quiet thing this week. Now let us go and do it in a hundred more. Pamberi nekuzvimiririra kwehutano hwedu — forward with the sovereignty of our own health.

A Clear-Eyed Word
Celebration and realism belong together. A world-class regulator is a doorway, not a destination: the prize is only fully claimed if investment, factories and skilled jobs now rise to walk through it, and if Level 4 is maintained — the WHO’s top rung is defined by continuous improvement, not a one-day certificate. The achievement is real and rare. The work of turning it into medicine on shelves and money in the economy is what comes next.
They said a poor, sanctioned African country could never build something world-class. This week, in the exacting business of keeping a nation’s medicines safe, Zimbabwe quietly became one of only four countries on earth to reach the summit — and the first in Africa to stand there. Remember this the next time anyone tells you what we cannot do.
Tete Getty · TGRI · The Second Great Zimbabwe Economic Journal · Entry 40 · 2 July 2026
TeteGetty.com
The Second Great Zimbabwe Economic Journal · Entry 40 · Health, Industry & the Continent · 2 July 2026
Sources & further reading: The Medicines Control Authority of Zimbabwe (MCAZ, mcaz.co.zw) and the World Health Organisation on the Global Benchmarking Tool (GBT) and its four maturity levels — Level 1 (some elements exist) through Level 3 (a stable, well-functioning and integrated system) to Level 4 (an advanced system operating with continuous improvement, the highest tier). WHO (14 June 2024) and African Pharmaceutical Review on Zimbabwe reaching Maturity Level 3, with remarks by Dr Yukiko Nakatani (WHO Assistant Director-General for Access to Medicines and Health Products) and Dr Matshidiso Moeti (then WHO Regional Director for Africa), including the link to the future operationalisation of the African Medicines Agency (AMA). Bulawayo24 and Market Access Africa on MCAZ’s journey toward Level 4 and the reforms it required — digitalised dossier and inspection systems, strengthened pharmacovigilance, and the publication of public assessment reports (PAR) and public inspection reports (PIR) from 2025 — and on the fact that, before Zimbabwe, only Singapore (2022), South Korea (2022) and Saudi Arabia (2023) had attained Level 4 worldwide; remarks by MCAZ’s Head of Licensing and Enforcement, Ms Caroline Samatanga. Market Access Africa on MCAZ’s regulatory cooperation agreements (memoranda of understanding) with Zambia’s ZAMRA, Botswana’s BoMRA and South Africa’s SAHPRA. Peer-reviewed benchmarking studies (Therapeutic Innovation & Regulatory Science; Expert Review of Clinical Pharmacology) and PMC analyses on African regulatory strengthening and local manufacturing. The framing, the economic analysis and the conclusions are TGRI’s own editorial work; figures on maturity levels and member countries are as recorded by the WHO benchmarking system. This is analysis and celebration in the public interest, not medical or investment advice.
Produced by the Tete Getty Research Institute (TGRI) for TeteGetty.com, as Entry 40 of the Second Great Zimbabwe Economic Journal, in continuity with this journal’s long argument for beneficiation and self-reliance — now carried into the medicine cabinet. Written in the conviction that African excellence is not borrowed but built, and that the sovereignty of a people includes the power to make, test and trust their own medicines. Neither East nor West — Africa first. Republication with attribution welcome. © TeteGetty.com 2026

Leave a Reply

Trending

Discover more from TETEGETTY.com

Subscribe now to keep reading and get access to the full archive.

Continue reading